11/17/2025
"A new University College London study featuring 17,604 participants age 45 and up discovered that semaglutide -- a GLP-1 agonist found in weight-loss drugs like Ozempic and Wegovy -- decreases the risk of major adverse cardiovascular events, like a heart attack and stroke, in patients who were of a higher weight or dealing with obesity."
Research is showing that use of GLP-1's, like semaglutide, may have other health benefits besides regulating blood sugar and weightloss. If you are interested in learning more about semaglutide for weight loss, please call our office at 918.794.0701.
Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular events.